HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Poxviridae Infections

Subscribe to New Research on Poxviridae Infections

Virus diseases caused by the POXVIRIDAE.

Also Known As:

Infections, Poxviridae; Infections, Poxvirus; Infection, Poxviridae; Infection, Poxvirus; Milker Nodes; Milker's Node; Milkers Nodes; Node, Milker's; Nodes, Milker's; Poxviridae Infection; Poxvirus Infection; Milker's Nodes; Poxvirus Infections

Networked: 96 relevant articles (12 outcomes, 11 trials/studies)

Relationship Network

Disease Context: Research Results

Virus Diseases: 1820
- DNA Virus Infections: 41
  - Poxviridae Infections: 96

Related Diseases

1.	Smallpox (Variola)
2.	Vaccinia
3.	Molluscum Contagiosum
4.	Contagious Ecthyma (Orf)
5.	Infection

Experts

1.	De Clercq, Erik: 13 articles (10/2010 - 07/2002)
2.	Andrei, Graciela: 6 articles (12/2010 - 10/2006)
3.	Snoeck, Robert: 6 articles (12/2010 - 10/2006)
4.	Moss, Bernard: 3 articles (01/2014 - 08/2003)
5.	Crance, Jean-Marc: 3 articles (01/2011 - 12/2007)
6.	Garin, Daniel: 3 articles (01/2011 - 12/2007)
7.	Krecmerová, Marcela: 3 articles (10/2010 - 12/2007)
8.	Neyts, Johan: 3 articles (10/2010 - 01/2003)
9.	Chaudhri, Geeta: 3 articles (09/2009 - 09/2005)
10.	Karupiah, Gunasegaran: 3 articles (09/2009 - 09/2005)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Poxviridae Infections:

1.	cidofovir (Vistide)FDA Link 09/01/2000 - "The results of these studies establish the utility of cidofovir treatment of poxvirus infections in mice by intranasal route. " 01/01/2011 - "Currently the only therapeutic option for the treatment of poxvirus infections relies on the virostatic nulceosid analog cidofovir, although severe side effects and drug resistant strains have been described. " 12/01/2010 - "Cidofovir Activity against Poxvirus Infections." 12/01/2007 - "Our results demonstrate that compounds belonging to the newly synthesized ANPs, in addition to cidofovir, represent promising candidates for the treatment of poxvirus infections." 09/01/2004 - "Only one compound, cidofovir, has also proved efficacious against poxvirus infections in humans, i.e. "
2.	Smallpox Vaccine FDA Link 08/05/2003 - "Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses." 02/05/2008 - "These results suggest the feasibility of a subunit smallpox vaccine based on VARV antigen sequences to induce immunity against poxvirus infection." 06/01/2011 - "Considering a recent case of unusually severe cowpox virus infection in a young drug taker these data confirm a risk of "soft drugs" for acquiring poxvirus infection or enhancing side effects of the smallpox vaccine and perhaps also other live vaccines." 09/01/2010 - "However, there has been renewed interest in smallpox vaccine development due in part to zoonotic poxvirus infections and the possibility of a re-emergence of smallpox, as well as the fact that first-generation smallpox vaccines are associated with relatively rare, but severe, adverse reactions in some vaccinees. " 07/01/2002 - "Taken together, these data indicate that cidofovir should be effective in the therapy and short-term prophylaxis of smallpox and related poxvirus infections in humans, as well as the treatment of the complications of vaccinia that may arise in immunocompromised patients inadvertently inoculated with the smallpox vaccine (vaccinia)."
3.	VaccinesIBA 04/01/2005 - "Improved vaccines and therapies for virulent poxvirus infection are required, particularly in the light of recent threats of bioterrorism. " 11/25/2006 - "Recent studies have established the feasibility of subunit-based experimental vaccines to protect animals from lethal poxvirus infection. " 11/01/2012 - "Different kinds of vaccines starting from conventional inactivated/attenuated to recombinant protein-based vaccines have been used for control of poxvirus infections. " 06/05/2007 - "These results demonstrate that VRP may provide an effective alternative to vaccinia virus vaccines against poxvirus infection." 06/01/2011 - "Considering a recent case of unusually severe cowpox virus infection in a young drug taker these data confirm a risk of "soft drugs" for acquiring poxvirus infection or enhancing side effects of the smallpox vaccine and perhaps also other live vaccines."
4.	DNA (Deoxyribonucleic Acid)IBA 02/01/2000 - "The results reported on 42 skin biopsies from sheep suspected to have poxvirus infection, indicated that the assay could monitor simultaneously DNA extraction from skin biopsy samples and allow improved detection of capripoxvirus within 24 h of specimen receipt in the laboratory." 08/04/2006 - "The topoisomerase-DNA complex structures also provide a three-dimensional framework that may facilitate the rational design of therapeutic agents to treat poxvirus infections." 04/01/1980 - "Replication of milker's node virus (MNV) DNA begins 4 to 8 h postinfection, continues to 30 to 36 h postinfection in the cytoplasm of infected, primary bovine embryonic kidney cells, and is accompanied by an inhibition of host nuclear DNA synthesis. " 05/01/1968 - "Effect of poxvirus infection on host cell deoxyribonucleic acid synthesis." 01/01/2003 - "Should there be a threat of smallpox or other poxvirus infections, that could not be immediately controlled by vaccination, a therapeutic intervention could be envisaged based on several therapeutic strategies targeted at such cellular enzymes as IMP dehydrogenase, SAH hydrolase, OMP decarboxylase and CTP synthetase, as well as viral enzymes such as the DNA polymerase. "
5.	Monoclonal AntibodiesIBA 05/01/2002 - "Since drugs specific against poxvirus infections are limited, neutralizing monoclonal antibodies (mAbs) that are effective in vivo may be an important tool in controlling poxvirus infections. " 01/01/2012 - "Protection of rabbits and immunodeficient mice against lethal poxvirus infections by human monoclonal antibodies." 07/01/1991 - "The monoclonal antibodies produced were tested for crossreactivity with bovine papular stomatitis virus (BPS) and milker's node virus (MNV) by indirect immunofluorescence assay (IFA) and immunoblotting. "
6.	9- (3- hydroxy- 2- phosphonylmethoxypropyl)adenineIBA 01/01/1990 - "Phosphonylmethoxyalkylpurines and -pyrimidines offer great promise for both topical and systemic treatment of various DNA virus and retrovirus infections: HPMPA for the treatment of adeno-, herpes- and poxvirus infections, HPMPC for the treatment of herpesvirus (in particular CMV) infections, and PMEA and PMEDAP for the treatment of retrovirus (i.e. " 07/01/2007 - "From HPMPA originated three compounds, which have been approved by regulatory agencies worldwide for clinical use: (i) HPMPC [cidofovir (Vistide)] for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients, and "off label" for the treatment of polyoma-, papilloma-, adeno-, herpes- and poxvirus infections; (ii) PMEA [adefovir (in its oral prodrug form, adefovir dipivoxil (Hepsera)] for the treatment of chronic HBV (hepatitis B virus) infections, and (iii) PMPA [tenofovir (in its oral prodrug form, tenofovir disoproxil fumarate (Viread)] for the treatment of HIV infections (AIDS). "
7.	TetrapyrrolesIBA 05/28/2003 - "These tetrapyrroles were found to be active against two different virus strains, and against both enveloped and non-enveloped forms of the virus, indicating that these compounds may be broadly effective in their ability to inhibit poxvirus infection." 05/28/2003 - "Prevention of poxvirus infection by tetrapyrroles."
8.	Small Interfering RNA (siRNA)IBA 06/01/2009 - "Furthermore, we showed that a combined therapy using siRNA and cidofovir may be useful in the treatment of poxvirus infections."
9.	PyrimidinesIBA 01/01/1990 - "Phosphonylmethoxyalkylpurines and -pyrimidines offer great promise for both topical and systemic treatment of various DNA virus and retrovirus infections: HPMPA for the treatment of adeno-, herpes- and poxvirus infections, HPMPC for the treatment of herpesvirus (in particular CMV) infections, and PMEA and PMEDAP for the treatment of retrovirus (i.e. "
10.	OligodeoxyribonucleotidesIBA 11/01/2006 - "Enhancement of CD8+ T cell immunity in the lung by CpG oligodeoxynucleotides increases protective efficacy of a modified vaccinia Ankara vaccine against lethal poxvirus infection even in a CD4-deficient host."

Therapies and Procedures

1.	Therapeutics 01/01/2012 - "These problems have resulted in extensive efforts to develop potential therapeutics that can prevent or treat potentially lethal poxvirus infections in humans. " 01/01/2012 - "Concerns about the possible use of variola virus as a biological weapon as well as the need for therapeutics for the treatment or prevention of naturally acquired poxvirus infections or vaccination complications have led to the search for small molecule inhibitors of poxvirus replication. " 12/01/2008 - "The acyclic nucleoside phosphonate (ANP) family of drugs shows promise as therapeutics for treating poxvirus infections. "
2.	Drug Therapy (Chemotherapy) 06/01/2010 - "This dates back to 1950; and, although there is at present no single antiviral drug specifically licensed for the chemotherapy or -prophylaxis of poxvirus infections, numerous candidate compounds have been described over the past 50 years. " 02/01/2005 - "Antiviral chemotherapy facilitates control of poxvirus infections through inhibition of cellular signal transduction." 04/01/2001 - "Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections."
3.	Biological Therapy 03/01/2013 - "These results highlight the importance of VEGF expression in VV infection and have potential implications for the design of new strategies to prevent poxvirus infection and the development of future generations of oncolytic VV in combination with conventional or biological therapies."